Clinical features and treatment of bone marrow metastasis

Yang,Hongliang; He,Feng; Yuan,Tian; Xu,Wen; Cao,Zeng

doi:10.3892/ol.2023.13918

Clinical features and treatment of bone marrow metastasis

Authors:
- Hongliang Yang
- Feng He
- Tian Yuan
- Wen Xu
- Zeng Cao
View Affiliations

Affiliations: Institute of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300072, P.R. China, Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: June 16, 2023 https://doi.org/10.3892/ol.2023.13918
Article Number: 332
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone marrow metastasis (BMM) refers to the metastasis of malignant tumours originating from nonhematopoietic tissues to the bone marrow. The nonhematopoietic malignant tumour cells metastasize to the bone marrow via heterogeneous dissemination or direct invasion to form metastases and the bone marrow is infiltrated by tumour cells, resulting in the destruction of its structure and the development of haematopoietic disorders. In the present study, the clinical characteristics, prognosis and treatment of BMMs were investigated. The main clinical manifestations were moderate anaemia and thrombocytopenia. Out of 52 cases, a total of 18 patients were not treated and the remaining patients underwent chemotherapy, radiotherapy, surgery or autologous stem cell transplantation in the Affiliated Tumour Hospital of Tianjin Medical University from September 2010 to October 2021. The primary tumours of bone marrow metastatic cancer were usually neuroblastoma and tumours originating from the breast and stomach. When bone metastases occur, patients are not necessarily accompanied by BMMs. In the present study, bone metastases occurred mainly in patients with breast and prostate cancers. The median overall survival of patients treated with antitumor therapy was significantly higher than that of untreated patients (11.5 vs. 3.3 months P<0.01). For patients with BMM, it is of great importance to actively evaluate the patient's condition and select the appropriate treatment plan for improving their prognosis.

View Figures

View References

1	Clifton BA, Neill JS and Anderson MD: Treatment of Shh medulloblastoma with extraneural metastasis to the bone marrow. Current problems in cancer: Case Reports. 4:1001042021. View Article : Google Scholar : PubMed/NCBI
2	Shinden Y, Sugimachi K, Tanaka F, Fujiyoshi K, Kijima Y, Natsugoe S and Mimori K: Clinicopathological characteristics of disseminated carcinomatosis of the bone marrow in breast cancer patients. Mol Clin Oncol. 8:93–98. 2018.PubMed/NCBI
3	La Gioia A, Fiorini F and La Gioia N: Bone marrow involvement by metastatic invasive lobular breast cancer. Int J Lab Hematol. 44:40–41. 2022. View Article : Google Scholar : PubMed/NCBI
4	Fan HJ, Huang C, Su Y, Wang XD, Zhou YC, Duan C, Zhao W, Zhao Q, Jin M and Ma XL: Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children. Zhonghua Er Ke Za Zhi. 57:863–869. 2019.(In Chinese). PubMed/NCBI
5	Rani HS, Hui M, Manasa P, Uppin SG, Uppin MS, Paul TR and Sadashivudu G: Bone marrow metastasis of solid tumors: A study of 174 cases over 2 decades from a single institution in India. Indian J Hematol Blood Transfus. 38:8–14. 2022. View Article : Google Scholar : PubMed/NCBI
6	Edwards IR and Aronson JK: Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 356:1225–1229. 2000. View Article : Google Scholar
7	Rana NA, Mahmood A, Robert HM, Zahir S, Asghar MB and Riaz S: Laboratory evaluation and pathological features of bone marrow metastasis in non-haematological malignancies. J Coll Physicians Surg Pak. 32:1367–1369. 2022. View Article : Google Scholar : PubMed/NCBI
8	Hofbauer LC, Bozec A, Rauner M, Jakob F, Perner S and Pantel K: Novel approaches to target the microenvironment of bone metastasis. Nat Rev Clin Oncol. 18:488–505. 2021. View Article : Google Scholar : PubMed/NCBI
9	Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W and Islam SMB: Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma. Clin Mol Hepatol. 22:267–271. 2016. View Article : Google Scholar : PubMed/NCBI
10	Shi XB, Deng WX and Jin FX: Bone marrow metastatic neuroendocrine carcinoma with unknown primary site: A case report and review of the literature. World J Clin Cases. 10:11074–11081. 2022. View Article : Google Scholar : PubMed/NCBI
11	Kopp HG, Krauss K, Fehm T, Staebler A, Zahm J, Vogel W, Kanz L and Mayer F: Symptomatic bone marrow involvement in breast cancer-clinical presentation, treatment, and prognosis: A single institution review of 22 cases. Anticancer Res. 31:4025–4030. 2011.PubMed/NCBI
12	Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, et al: 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 377:1836–1846. 2017. View Article : Google Scholar : PubMed/NCBI
13	Park SH, Keller ET and Shiozawa Y: Bone marrow microenvironment as a regulator and therapeutic target for prostate cancer bone metastasis. Calcif Tissue Int. 102:152–162. 2018. View Article : Google Scholar : PubMed/NCBI
14	Ripp J, Diab O, Woodroof J and Sun W: Colorectal adenocarcinoma presenting with isolated metastasis to the cortical bone and bone marrow: A case report and review of the literature. Clin Colorectal Cancer. 20:e150–e154. 2021. View Article : Google Scholar : PubMed/NCBI
15	Jafari A, Fairfield H, Andersen TL and Reagan MR: Myeloma-bone marrow adipocyte axis in tumour survival and treatment response. Br J Cancer. 125:775–777. 2021. View Article : Google Scholar : PubMed/NCBI
16	Fairfield H, Dudakovic A, Khatib CM, Farrell M, Costa S, Falank C, Hinge M, Murphy CS, DeMambro V, Pettitt JA, et al: Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype. Cancer Res. 81:634–527. 2021. View Article : Google Scholar : PubMed/NCBI
17	Dello Spedale Venti M, Palmisano B, Donsanten S, Farinacci G, Adotti F, Coletta I, Serafini M, Corsi A and Riminucci M: Morphological and immunophenotypical changes of human bone marrow adipocytes in marrow metastasis and myelofibrosis. Front Endocrinol (Lausanne). 13:8823792022. View Article : Google Scholar : PubMed/NCBI
18	DA Silva A, Levy C, Allouache D, Hrab I, Morel A, Faveyrial A, Gunzer K, Johnson A, Segura C, Licaj I, et al: Efficacy and safety of weekly paclitaxel in breast cancer with symptomatic bone marrow infiltration. Anticancer Res. 40:2955–2960. 2020. View Article : Google Scholar : PubMed/NCBI
19	Braun S, Vogl FD, Janni W, Marth C, Schlimok G and Pantel K: Evaluation of bone marrow in breast cancer patients: Prediction of clinical outcome and response to therapy. Breast. 12:397–404. 2003. View Article : Google Scholar : PubMed/NCBI
20	Buschhaus JM, Humphries BA, Eckley SS, Robison TH, Cutter AC, Rajendran S, Haley HR, Bevoor AS, Luker KE and Luker GD: Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow. Oncogene. 39:5529–5662. 2020. View Article : Google Scholar
21	Arya L, Sundriyal D, Bhandari R, Srivastava R and Sehrawat A: Bone marrow metastases from solid organ cancer in adults. Indian J Surg Oncol. 12:545–548. 2021. View Article : Google Scholar : PubMed/NCBI
22	Mora J: Autologous stem-cell transplantation for high-risk neuroblastoma: Historical and critical review. Cancers (Basel). 14:25722022. View Article : Google Scholar : PubMed/NCBI
23	Moreno L, Guo D, Irwin MS, Berthold F, Hogarty M, Kamijo T, Morgenstern D, Pasqualini C, Ash S, Potschger U, et al: A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An international neuroblastoma risk group project. Pediatr Blood Cancer. 68:e287942021. View Article : Google Scholar : PubMed/NCBI
24	Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, et al: Effect of tandem autologous stem cell transplant vs singletransplant on event-free survival in patients with high-risk neuroblastoma: A randomized clinical trial. JAMA. 322:746–755. 2019. View Article : Google Scholar : PubMed/NCBI
25	Demir L, Akyol M, Bener S, Payzin KB, Erten C, Somali I, Can A, Dirican A, Bayoglu V, Kucukzeybek Y, et al: Prognostic evaluation of breast cancer patients with evident bone marrow metastasis. Breast J. 20:279–287. 2014. View Article : Google Scholar : PubMed/NCBI
26	Hiroshige T and Eguchi Y: Prostate cancer with disseminated carcinomatosis of the bone marrow: Two case reports. Mol Clin Oncol. 7:233–236. 2017.PubMed/NCBI